U.S. Exchanges

list of publicly traded healthcare companies cancer

Comprehensive directory of oncology market leaders and biotech innovators developing next-generation ADC, CAR-T, and immunotherapy cancer treatments for 2026.

$120B Top Market Cap
22 Phase 3 Readouts H2
45% ADC Trial Success
Apr 2026 Last Updated
This page is for informational and educational purposes only and does not constitute investment advice. Always consult a qualified financial professional before making investment decisions.

Navigating the list of publicly traded healthcare companies cancer is critical for investors seeking exposure to the most innovative segment of the complete healthcare directory. As of April 2026, the oncology market is being redefined by antibody-drug conjugates (ADCs) and bispecific antibodies, which are showing clinical success rates nearly triple those of traditional chemotherapy. While large-cap giants anchor the sector with stable revenues, many investors look to mid-cap cancer companies for a balance of proven assets and high-growth potential. For those with a higher risk tolerance, tracking breakthrough assets within small-cap cancer research can offer significant upside ahead of pivotal Phase 3 readouts. This guide provides a structured look at the firms leading the fight against cancer across major U.S. stock exchanges.

What to Know

Key Takeaways

01 ADC Market Surge

Antibody-drug conjugates are projected to hit $15B in peak sales by 2030, with Gilead and AstraZeneca leading the approved category. This technology is a primary driver for biotech companies overview analysis.

02 Immunotherapy Dominance

Regeneron and Merck continue to dominate the PD-1/immuno-oncology landscape, focusing on combination therapies to overcome treatment resistance in solid tumors.

03 Trial Success Shifts

Next-gen modalities like bispecifics are seeing success rates of 35-45%, a massive improvement over the historical oncology trial average of 10-15%.

04 Radiopharma Expansion

Targeted radiopharmaceuticals are emerging as a $5B market opportunity, providing a specialized vertical for investors alongside traditional cancer diagnostics leaders.

Market Data

Top list of publicly traded healthcare companies cancer by Market Cap (2026)

The following table highlights the market leaders in oncology development, tracking valuation alongside lead assets and anticipated 2026 clinical catalysts.

Rank Ticker Company Modality Market Cap Lead Asset Phase 2026 Catalyst
1 AZN AstraZeneca ADC/IO $220B Enhertu Approved Q3 Expansion Data
2 REGN Regeneron IO/Bispecific $120B Libtayo Approved Q3 Combo Readout
3 GILD Gilead Sciences ADC/CAR-T $95B Trodelvy Approved New Indication PDUFA
4 MRK Merck & Co. Immunotherapy $320B Keytruda Approved Sasanlimab PDUFA
5 INCY Incyte Corp Small Molecule $14B Opzelura Expansion Phase 3 Readout
6 EXEL Exelixis TKI/ADC $8B Cabometyx Approved ADC Pipeline Entry
7 BMRN BioMarin Rare Oncology $16B Pipeline Phase 2/3 Clinical Data H2
8 AMGN Amgen Bispecific $150B Blincyto Approved Myeloma Readout
9 NVS Novartis Radiopharma $210B Pluvicto Approved Label Expansion
10 BMY Bristol Myers IO/CAR-T $105B Opdivo Approved Combo Approvals
Market data is approximate and for informational purposes only. Data reflects early Q2 2026 figures. Not a recommendation to buy or sell.
full directory

list of publicly traded healthcare companies cancer — Complete Company List

Cancer Focused Companies

A list of publicly traded cancer companies can be found by scrolling down or you can access a list of the companies in each group through the industry links on this page.

Industry Links: Cancer

Cancer: IPOs in 2016

Cancer: Comparison Widgets

Diagnostics

Cancer: Mid-Cap Stocks

Cancer: Small-Cap Stocks

Cancer: Micro-Cap Stocks

Cancer: Nano-Cap Stocks

Related Links

Investor Awareness

Risks & Considerations

Clinical Trial Failure

Even with improved success rates for ADCs, a negative Phase 3 readout can wipe out 50% or more of a small or mid-cap company's valuation in a single trading session.

FDA Regulatory Uncertainty

Meeting primary endpoints does not guarantee approval; the FDA may require additional safety data or survival benefit evidence, delaying commercialization by years.

Cash Runway Constraints

Early-stage oncology biotechs often burn hundreds of millions annually; companies with less than 12 months of cash runway face extreme dilution risk from secondary offerings.

Exclusivity and Patent Cliffs

Large-cap cancer leaders face looming biosimilar competition for blockbuster drugs, necessitating constant pipeline renewal through expensive M&A activity.

These risk factors are for educational purposes only and are not exhaustive. Individual investment decisions should be based on thorough due diligence.
Common Questions

Frequently Asked Questions

Regeneron (REGN) leads at $120B with Libtayo/PD-1 dominance, followed by Gilead (GILD) at $95B (Trodelvy ADC) and AstraZeneca (AZN) at $220B (Enhertu). Smaller pure-plays like Exelixis (EXEL) maintain significant valuations on their flagship assets.
The 2026 PDUFA calendar features Merck (MRK) for sasanlimab, Bristol Myers (BMY) for Opdivo combinations, and Gilead (GILD) for additional Trodelvy indications. Bispecifics from Amgen and Roche are also targeting key 2026 readouts.
Gilead, AstraZeneca, and Pfizer (via Seagen) lead the approved ADC category. $15B in peak sales is projected for top ADCs by 2030, with Merck and BMS advancing next-gen payloads.
Incyte offers a strong cash position, while Exelixis generates nearly $2B in annual revenue from Cabometyx. BioMarin is also advancing rare cancer assets with managed cash burn.
ADC and bispecific tailwinds currently favor mid and large-caps with proven clinical platforms. Trial success rates are rising, though CAR-T expansion into solid tumors remains a high-risk area.
The SPDR S&P Biotech (XBI) is roughly 45% oncology weighted, while the iShares Nasdaq Biotech (IBB) offers 38% cancer exposure. ARK Genomic (ARKG) focuses on early-stage immuno-oncology.
Gilead and BMS/J&J dominate the approved CAR-T space with significant 2025 sales. Allogene is a notable name advancing "off-the-shelf" CAR-T for solid tumors.
Radiopharma (e.g., Novartis Pluvicto) delivers localized radiation directly to cancer cells. It is currently a fast-growing market, specifically targeting PSMA+ prostate cancer.
Last updated April 2026 · Data sourced from U.S. exchange filings

Providing data-driven insights for smart investing in public markets, crypto, and ETFs.

Facebook Twitter Youtube Linkedin

Quick Links

Stocks

Crypto

ETFs

Tools

Quick Links

News & Insights

About Us

Contact

Quick Links

Privacy Policy

Terms of Service

Disclaimer

Disclosures

Informational only, not financial advice.

© 2026 InvestSnips. All rights reserved